company background image
INOV

Inovalon HoldingsNasdaqGS:INOV Stock Report

Market Cap

US$6.4b

7D

0.5%

1Y

122.1%

Updated

24 Nov, 2021

Data

Company Financials +
INOV fundamental analysis
Snowflake Score
Valuation0/6
Future Growth4/6
Past Performance5/6
Financial Health1/6
Dividends0/6

INOV Stock Overview

Inovalon Holdings, Inc. provides cloud-based platforms for data-driven healthcare.

Inovalon Holdings Competitors

Veeva Systems

NYSE:VEEV

US$44.4b

Cerner

NasdaqGS:CERN

US$21.3b

Change Healthcare

NasdaqGS:CHNG

US$6.5b

Evolent Health

NYSE:EVH

US$2.3b

Price History & Performance

Summary of all time highs, changes and price drops for Inovalon Holdings
Historical stock prices
Current Share PriceUS$41.06
52 Week HighUS$41.06
52 Week LowUS$17.56
Beta0.53
1 Month Change0.69%
3 Month Change1.16%
1 Year Change122.07%
3 Year Change229.80%
5 Year Change167.49%
Change since IPO52.07%

Recent News & Updates

Shareholder Returns

INOVUS Healthcare ServicesUS Market
7D0.5%-4.6%-2.7%
1Y122.1%-7.5%21.3%

Return vs Industry: INOV exceeded the US Healthcare Services industry which returned -4.5% over the past year.

Return vs Market: INOV exceeded the US Market which returned 24.3% over the past year.

Price Volatility

Is INOV's price volatile compared to industry and market?
INOV volatility
INOV Average Weekly Movement0.6%
Healthcare Services Industry Average Movement8.8%
Market Average Movement5.9%
10% most volatile stocks in US Market15.1%
10% least volatile stocks in US Market2.2%

Stable Share Price: INOV is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 1% a week.

Volatility Over Time: INOV's weekly volatility (1%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19981,836Keith Dunleavyhttps://www.inovalon.com

Inovalon Holdings, Inc. provides cloud-based platforms for data-driven healthcare. It operates Inovalon ONE Platform, an integrated, real-time cloud native platform that interconnect with the healthcare ecosystem to aggregate and analyze data in real-time, as well as empowers the application in resulting insights. The company also operates myABILITY software platform, an integrated set of cloud-based applications for providers that offers connectivity, administrative, clinical and quality analysis, management, and performance improvement capabilities to acute, post-acute, and ambulatory point-of-care provider facilities.

Inovalon Holdings Fundamentals Summary

How do Inovalon Holdings's earnings and revenue compare to its market cap?
INOV fundamental statistics
Market CapUS$6.37b
Earnings (TTM)US$50.43m
Revenue (TTM)US$749.59m

126.4x

P/E Ratio

8.5x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
INOV income statement (TTM)
RevenueUS$749.59m
Cost of RevenueUS$201.47m
Gross ProfitUS$548.12m
ExpensesUS$497.69m
EarningsUS$50.43m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)0.32
Gross Margin73.12%
Net Profit Margin6.73%
Debt/Equity Ratio121.7%

How did INOV perform over the long term?

See historical performance and comparison

Valuation

Is Inovalon Holdings undervalued compared to its fair value and its price relative to the market?

126.4x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: INOV ($41.06) is trading above our estimate of fair value ($31.7)

Significantly Below Fair Value: INOV is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: INOV is poor value based on its PE Ratio (126.4x) compared to the US Healthcare Services industry average (105.8x).

PE vs Market: INOV is poor value based on its PE Ratio (126.4x) compared to the US market (17.8x).


Price to Earnings Growth Ratio

PEG Ratio: INOV is poor value based on its PEG Ratio (3.7x)


Price to Book Ratio

PB vs Industry: INOV is overvalued based on its PB Ratio (8.3x) compared to the US Healthcare Services industry average (4.7x).


Future Growth

How is Inovalon Holdings forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?

34.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: INOV's forecast earnings growth (34.1% per year) is above the savings rate (2%).

Earnings vs Market: INOV's earnings (34.1% per year) are forecast to grow faster than the US market (14.4% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: INOV's revenue (11.7% per year) is forecast to grow faster than the US market (10% per year).

High Growth Revenue: INOV's revenue (11.7% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if INOV's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Inovalon Holdings performed over the past 5 years?

3.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: INOV has high quality earnings.

Growing Profit Margin: INOV's current net profit margins (6.7%) are higher than last year (0.9%).


Past Earnings Growth Analysis

Earnings Trend: INOV's earnings have grown by 3.3% per year over the past 5 years.

Accelerating Growth: INOV's earnings growth over the past year (784.3%) exceeds its 5-year average (3.3% per year).

Earnings vs Industry: INOV earnings growth over the past year (784.3%) exceeded the Healthcare Services industry 4.8%.


Return on Equity

High ROE: INOV's Return on Equity (6.8%) is considered low.


Financial Health

How is Inovalon Holdings's financial position?


Financial Position Analysis

Short Term Liabilities: INOV's short term assets ($366.3M) exceed its short term liabilities ($152.6M).

Long Term Liabilities: INOV's short term assets ($366.3M) do not cover its long term liabilities ($1.1B).


Debt to Equity History and Analysis

Debt Level: INOV's net debt to equity ratio (107.5%) is considered high.

Reducing Debt: INOV's debt to equity ratio has increased from 37.1% to 121.7% over the past 5 years.

Debt Coverage: INOV's debt is not well covered by operating cash flow (12.5%).

Interest Coverage: INOV's interest payments on its debt are not well covered by EBIT (2x coverage).


Balance Sheet


Dividend

What is Inovalon Holdings's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate INOV's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate INOV's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if INOV's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if INOV's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of INOV's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.2yrs

Average management tenure


CEO

Keith Dunleavy (52 yo)

7.83yrs

Tenure

US$211,827

Compensation

Dr. Keith R. Dunleavy, M.D., has been the Chairman of Inovalon Holdings, Inc. since 2006 and its Chief Executive Officer since 1998 and is its Founder. Dr. Dunleavy is responsible for the overall execution...


CEO Compensation Analysis

Compensation vs Market: Keith's total compensation ($USD211.83K) is below average for companies of similar size in the US market ($USD6.20M).

Compensation vs Earnings: Keith's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: INOV's management team is considered experienced (2.2 years average tenure).


Board Members

Experienced Board: INOV's board of directors are considered experienced (5.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Inovalon Holdings, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Inovalon Holdings, Inc.
  • Ticker: INOV
  • Exchange: NasdaqGS
  • Founded: 1998
  • Industry: Health Care Technology
  • Sector: Healthcare
  • Market Cap: US$6.374b
  • Shares outstanding: 155.25m
  • Website: https://www.inovalon.com

Number of Employees


Location

  • Inovalon Holdings, Inc.
  • 4321 Collington Road
  • Bowie
  • Maryland
  • 20716
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/11/24 23:16
End of Day Share Price2021/11/23 00:00
Earnings2021/09/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.